Table 2.
Results with all predictors
| Models | ||||
|---|---|---|---|---|
| Variable | Post-traumatic stress model | Re-experiencing model | Avoidance model | Hyperarousal model |
| TPS | 2.160 (1.518; 3.093); <0.001 | – | – | – |
| REX | – | 1.721 (1.261; 2.350); <0.001 | – | – |
| AVO | – | – | 1.771 (1.270; 2.477); <0.001 | – |
| HYP | – | – | – | 2.070 (1.467; 2.920); <0.001 |
| CDAI | 1.283 (0.920; 1.939); 0.033 | 1.514 (1.087; 2.106); 0.004 | 1.394 (0.920; 1.939); 0.024 | 1.394 (1.017; 1.939); 0.007 |
| Female sex B | 1.136 (0.586; 2.201); 0.621 | 1.357 (0.717; 2.569); 0.217 | 1.148 (0.594; 2.216); 0.590 | 1.207 (0.632; 2.306); 0.454 |
| Age (years) | 1.000 (0.972; 1.028); 0.992 | 1.000 (0.974; 1.027); 0.994 | 0.994 (0.966; 1.022); 0.554 | 1.003 (0.977; 1.031); 0.752 |
| Disease duration | 0.985 (0.948; 1.023); 0.307 | 0.988 (0.952; 1.024); 0.380 | 0.988 (0.951; 1.026); 0.396 | 0.981 (0.946; 1.018); 0.183 |
| Hospitalisation days | 0.994 (0.957; 1.032); 0.661 | 0.994 (0.957; 1.032); 0.676 | 0.995 (0.958; 1.034); 0.760 | 0.994 (0.958; 1.032); 0.695 |
| 5-Aminosalycilates B | 0.974 (0.400; 2.370); 0.940 | 0.920 (0.386; 2.196); 0.805 | 0.991 (0.408; 2.411); 0.980 | 0.911 (0.381; 2.179); 0.783 |
| Sulfasalazin B | 0.025 (0.025; 7.425); 0.447 | 0.436 (0.026; 7.329); 0.449 | 0.353 (0.021; 5.925); 0.341 | 0.429 (0.025; 7.359); 0.443 |
| Steroids B | 0.813 (0.371; 1.783); 0.497 | 0.951 (0.451; 2.004); 0.862 | 0.801 (0.366; 1.753); 0.466 | 0.859 (0.400; 1.841); 0.607 |
| Immunosuppressors B | 0.614 (0.317; 1.191); 0.058 | 0.660 (0.347; 1.255); 0.096 | 0.637 (0.330; 1.231); 0.078 | 0.623 (0.326; 1.188); 0.059 |
| Anti-TNF α B | 1.262 (0.565; 2.820); 0.456 | 1.340 (0.613; 2.929); 0.335 | 1.230 (0.552; 2.738); 0.506 | 1.312 (0.599; 2.873); 0.373 |
| Antibiotics B | 0.363 (0.035; 3.737); 0.263 | 0.543 (0.070; 4.188); 0.442 | 0.398 (0.038; 4.185); 0.313 | 0.608 (0.068; 5.441); 0.559 |
| Smoking B | 1.076 (0.557; 2.077); 0.775 | 1.114 (0.588; 2.112); 0.663 | 1.092 (0.567; 2.103); 0.730 | 1.149 (0.606; 2.181); 0.576 |
| BMI | 0.596 (0.395; 0.894); 0.001 | 0.624 (0.420; 0.932); 0.002 | 0.624 (0.413; 0.937); 0.003 | 0.615 (0.411; 0.919); 0.002 |
Values are ORs (99% CI) and corresponding p values.
The OR of disease deterioration for each variable is included. If no unit is specified, quantitative variables indicate ORs for 1 SD. Binary variables (yes/no) are distinguished by a ‘B’. Disease duration is indicated in years. Hospitalisation days refers to hospitalisations related to Crohn's disease.
Total Post-traumatic Stress (TPS) Model (457 (97.6%) valid cases): −2×ln(likelihood)=415; RE-experiencing (REX) Model (465 (99.3%) valid cases): −2×ln(likelihood)=434; Avoidance (AVO) Model (462 (98.7%) valid cases): −2×ln(likelihood)=419; Hyperarousal (HYP) Model (459 (98.1%) valid cases): −2×ln(likelihood)=431; Control Model (465 (99.3%) valid cases): −2×ln(likelihood)=455; −2×ln(likelihood ratio PDS/control variables)=40, p<0.001; −2×ln(likelihood ratio REX/control variables) =21, p<0.001; −2×ln(likelihood ratio AVO/control variables)=36, p<0.001; −2×ln(likelihood ratio ARO/control variables)=24, p<0.001.
BMI, body mass index; CDAI, Crohn's Disease Activity Index; TNF, tumour necrosis factor.